top of page

AI Approach
About
Missions Objectives & Values
Leadership & Governance
Patient Focus
Missions Objectives & Values
Leadership & Governance
Patient Focus
Pipeline
News
Reach Out

Discussion at Davos 2025

Dec 15, 2025
0 min read

https://www.youtube.com/watch?v=i1kggH4MAM4

Company news

© 2025 Oddifact. All rights reserved.

ODDIFACT develops and licenses Orphan Drug Designations (ODDs). An ODD is not an approved drug, treatment, or therapy, and does not imply safety, efficacy, or regulatory approval.
ODDIFACT provides neither medical advice nor treatment recommendations. Only qualified healthcare professionals can determine what therapies are appropriate for individual patients.
We disclaim all liability for any use, misuse, or interpretation of ODDs developed or licensed by our company.

Company Information:

Oddifact SAS: Company with registered capital of 100 000 euros.

Registration in the trade and companies register under number 985 380 138 R.C.S. Paris, France.

Activity (NAF/APE): Computer programming (62.01Z)

The Publication Director is the president of Oddifact

The development and integration of the website are provided by Oddifact

The website is hosted by Wix

Menu

Home

AI Approach

About

Pipeline

News

Reach out

Address

3 Villa Poirier, 75015 Paris, France

Contact Us

contact@oddifact.com

AI Approach
About
Pipeline
News
Reach Out

bottom of page